Psoriasis-like Skin Reactions during TNF-α Blockers Therapy
Authors:
P. Kozub 1; Z. Szép 2; M. Šimaljaková 1
Authors‘ workplace:
Dermatovenerologická klinika LF UK a UN v Bratislave
prednosta prof. MUDr. Mária Šimaljaková, PhD.
1; CYTOPATHOS, spol. s r. o., laboratórium bioptickej a cytologickej diagnostiky, Bratislava
prednosta doc. MUDr. Dušan Daniš, CSc.
2
Published in:
Čes-slov Derm, 86, 2011, No. 4, p. 186-192
Category:
Pharmacologyand Therapy, Clinical Trials
Overview
Biological therapy with TNF-α blockers represents the top in the management of some inflammatory diseases, in which cytokine TNF-α play a pathogenetical role, in dermatology, rheumatology and gastroenterology. These diseases include psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, Crohn’s disease and ulcerative colitis. TNF-α blockers have been successfully used in the therapy of psoriasis vulgaris since 2004. However, the paradoxical skin reactions including psoriasis-like eruptions appear during therapy with etanercept, adalimumab and infliximab in various intervals of treatment independently of the indication. Article reviews the psoriasis-like reactions occurring during TNF-α inhibitors therapy and the possibilities of their treatment.
Key words:
TNF-α blockers – psoriasis-like eruptions
Sources
1. BENÁKOVÁ, N., ŠTORK, J. Léčba psoriázy biologiky. Konsenzuální doporučené postupy České dermatologické společnosti ČLS JEP 2006, Čes.-slov. Derm., 81, 2006, 4, s. 1–11.
2. CHEN, L. A., SU, L. H., CHANG, Y. J., HSU, Y. L., TSAI, T. H. New-onset psoriasis associated with etanercept therapy. J. Dermatol., 2010, 37, p. 378–380.
3. COHEN, J. D., BOURNERIAS, I., BUFFARD, V., PAUFLER, A., CHEVALIER, X., BAGOT, M. ET AL. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J. Rheumatol., 2007, 34, p. 380–385.
4. COLLAMER, A. N., GUERRERO, K. T., HENNING, J. S., BATTAFARANO, D. F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum., 2008, 59, 7, p. 996–1001.
5. CONKLIN, L. S., COHEN, B., WILSON L, CUFFARI C, OLIVA-HEMKER M. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn’s disease. Nat. Rev. Gastroenterol. Hepatol., 2010, 7, p. 174–177.
6. DE GANNES, G. C., GHOREISHI, M., POPE, J., RUSSELL, A., BELL, D., ADAMS, S. et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch. Dermatol., 2007, 143, p. 223–231.
7. DUTZ, J. P. Tumor necrosis alpha inhibition and palmoplantar pustulosis: Janus-faced therapy? J. Rheumatol., 2007, 34, p. 247–249.
8. FIORINO, G., ALLEZ, M., MALESCI, A., DANESE, S. Review article: anti-TNFa induced psoriasis in patients with inflammatory bowel disease. Alliment Pharmacol. Ther., 2009, 29, p. 921–927.
9. HARRISON, M. J., DIXON, W. G., WATSON, K. D., KING, Y., GROVES, R., HYRICH, K. L. et al. Rates of new-onset of psoriasis in patients with rheumatoid arthritis receiving anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis., 2009, 68, p. 209–215.
10. KO, J. M., GOTTLIEB, A. B., KERBLESKI, J. F. Induction and exacerbation of psoriasis with TNFa-blockade therapy: a review and analysis of 127 cases. J. Dermatol. Treat., 2009, 20, p. 100.
11. PALUCKA, A. K., BLANCK, J. P., BENNETT, L. et al. Cross-regulation of TNF and IFNa in immune diseases. Proc. Natl. Acad. Sci., USA, 2005, 102, p. 3372–3377.
12. SARI, I., AKAR, S., BIRLIK, M., SIS, B., ONEN, F., AKKOC, N. Anti-tumor necrosis factor-alpha-induced psoriasis. J. Rheumatol., 2006, 33, p. 1411–1414.
13. SENESCHAL, J., LEPREUX, S., BOUYSSOU-GAUTHIER, M. L., HÉLIOT-HOSTEN, I., ECONOMU, A., DEHAIS, J. et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm. Venereol., 2007, 87, p. 77–80.
14. SENESCHAL, J., MILPIED, P., VERGIER, B. et al. Cytokine imbalance with increased production of interferon-a in psoriasiform eruptions associated with antitumour necrosis factor-a treatments. Br. J. Dermatol., 2009, 161, 5, p. 1081–1088.
15. SFIKAKIS, P. P., ILIOPOULOS, A., ELEZOGLOU, A., KITTAS, C., STRATIGOS, A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum, 2005, 52, 8, p. 2513–2518.
16. VEREA, M. M., DEL POZO, J., YEBRA-PIMENTEL, M. T. et al. Psoriasiform eruption induced by infliximab. Ann. Pharmacother., 2004, 38, p. 54–57.
17. VIGUIER, M., RICHETTE, P., BACHELEZ, H., WENDLING, D., AUBIN, F. Manifestations cutanées paradoxales des anti-TNF-alpha. Ann. Derm. Vener., 2010, 137, p. 64–71.
18. WENDLING, D., BALBLANC, J. C., BRIANCON, D., BROUSSE, A., LOHSE, A., DEPREZ, P. et al. Onset or exacerbation of cutaneous psoriasis during TNF-alpha antagonist therapy. Joint Bone Spine, 2008, 75, p. 315–318.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2011 Issue 4
Most read in this issue
- Red Sea Coral Contact Dermatitis
- Immunofluorescence in Dermatology
- Psoriasis-like Skin Reactions during TNF-α Blockers Therapy
- Our Experience with Ustekinumab for the Treatment of Psoriasis